From Nasdaq, Inc.:

INmune Bio Inc. (INMB) has been given the green light by the FDA to lift the full clinical hold on their Alzheimer’s disease clinical trial program. The phase II trial is set to finish enrolling the last patient by mid-2024, with top line data expected about six months later. CEO RJ Tesi has stated that the company’s main objective is to complete the Phase II program in 2024 and hold an end-of-Phase II meeting with the FDA in early 2025 to confirm the planned global Phase III trial. This trial will include sites in the U.S., Canada, U.K., E.U., and Pacific Rim.

For more health news, visit rttnews.com.



Read more: INmune Bio: FDA Removes Clinical Hold For Alzheimer’s Disease Program